Key Highlights

  • Revenue of USD 1.22 million beat the USD 0.80 million estimate, while loss per share was USD 0.15.
  • Loss before taxes was USD 2.2 million against USD 4.3 million, and the nine-month net loss was USD 11.2 million.
  • Cash, cash equivalents and short-term investments totaled USD 9.9 million, and the filing includes a Going Concern note.
  • The FDA accepted a tab-cel resubmission in October 2026 with a March 31, 2027 target action date.

Atara Biotherapeutics (NASDAQ:ATRA), a cell therapy company, reported third quarter 2026 Revenue of USD 1.22 million, above the USD 0.80 million estimate. Loss per share of USD 0.15 was wider than the estimated USD 0.13 loss. Loss before income taxes was USD 2.2 million against USD 4.3 million a year earlier.

For the nine months, the company reported a net loss of USD 11.2 million against Net Income of USD 36.1 million in the prior-year period. The filing states commercialization revenue in the current period relates solely to ongoing regulatory activities and clinical vial sales, resulting in significantly lower revenue than a year earlier.

Tab-cel Regulatory Status and Partner Agreements

Tab-cel is in Phase 3 development in the United States for patients with EBV-associated post-transplant lymphoproliferative disease who have failed rituximab or rituximab plus chemotherapy. The filing states the FDA accepted the resubmission in October 2026, with a March 31, 2027 target action date. Under the amended commercialization agreement with Pierre Fabre, the company transferred clinical and development responsibility in July 2025 and agreed to reduce the milestone payment due upon BLA approval of tab-cel to USD 31.0 million.

The filing also describes a financing agreement with HCRx under which the company received USD 31 million in exchange for a portion of tiered royalties and certain milestone payments, capped between 185% and 250% of the Investment depending on timing.

Cash and Going Concern Note

Cash, cash equivalents and short-term investments totaled USD 9.9 million at September 30, 2026, against USD 8.5 million at year end, and the accumulated Deficit was USD 2.0 billion. The filing states these resources are not sufficient to fund planned operations for at least 12 months after issuance of the financial statements, and that the company concluded substantial doubt exists about its ability to continue as a going concern. USD 78.3 million of common stock remained available for sale under its 2023 at-the-market facility.

Legal Disclosure and Items to Follow

The filing's Legal Proceedings item describes a putative Shareholder class action, Kuang v. Atara Biotherapeutics, Inc., et al., No. 2:26-cv-03083, filed on March 23, 2026 in the United States District Court for the Central District of California against the company and certain current and former officers. It asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The filing states the company believes the allegations are without merit and intends to defend, and that it has not accrued a liability. The matter is reported as stated and is flagged for human legal review.

The items to follow are the FDA action date, financing, cash use and developments in the class action.